Thank you allI appreciate your feedback. There is a lot of intelligent discussion here on the subject.
When I last spoke to Gord about the future plans for clinical trials a lot of things were up in the air. Whether they'll go as a device vs. drug. Will the FDA allow them to proceed with Dispersin as a device (and yes they have given a nod in this direction in the past, but nothing is guaranteed). Can the army accelerate things. What are the advantages and disadvantages of all these approaches.
I think the company is working through all these options and once they figure out what is best for DispersinB they will announce it. The good thing is whatever the approach, it will be a lot quicker compared to a normal drug clinical trials process.
To me the exact timeline and specifics of the clinical trials are not as important as the funding and the science. Funding has for a long time been the weak-point for KNE, and now that has been resolved through the last round of financing. The science seems superb. In the long run I think we will do fine.
Cheers,
TB